Literature DB >> 31632761

Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer.

Giuseppe Lamberti1, Elisa Andrini1, Biagio Ricciuti2.   

Abstract

Entities:  

Year:  2019        PMID： 31632761      PMCID： PMC6783754          DOI： 10.21037/jtd.2019.08.104

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

2.  Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Marcello Tiseo; Roberta Andreoli; Francesco Gelsomino; Paola Mozzoni; Cinzia Azzoni; Marco Bartolotti; Beatrice Bortesi; Matteo Goldoni; Enrico Maria Silini; Giuseppe De Palma; Antonio Mutti; Andrea Ardizzoni
Journal:  Lung Cancer       Date:  2013-12-12       Impact factor: 5.705

3.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

4.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

5.  First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

Authors:  Akira Inoue; Kunihiko Kobayashi; Kazuhiro Usui; Makoto Maemondo; Shoji Okinaga; Iwao Mikami; Masahiro Ando; Koichi Yamazaki; Yasuo Saijo; Akihiko Gemma; Hitoshi Miyazawa; Tomoaki Tanaka; Kenji Ikebuchi; Toshihiro Nukiwa; Satoshi Morita; Koichi Hagiwara
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 6.  Lung Cancer in the Older Patient.

Authors:  Julie A Barta; Ralph G Zinner; Michael Unger
Journal:  Clin Geriatr Med       Date:  2017-08-19       Impact factor: 3.076

7.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Authors:  James Chih-Hsin Yang; Myung-Ju Ahn; Dong-Wan Kim; Suresh S Ramalingam; Lecia V Sequist; Wu-Chou Su; Sang-We Kim; Joo-Hang Kim; David Planchard; Enriqueta Felip; Fiona Blackhall; Daniel Haggstrom; Kiyotaka Yoh; Silvia Novello; Kathryn Gold; Tomonori Hirashima; Chia-Chi Lin; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

8.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

9.  Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.

Authors:  Shang-Gin Wu; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  ERJ Open Res       Date:  2017-07-12

10.  Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yasuhiro Kato; Yukio Hosomi; Kageaki Watanabe; Makiko Yomota; Shoko Kawai; Yusuke Okuma; Kaoru Kubota; Masahiro Seike; Akihiko Gemma; Tatsuru Okamura
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895
View more
  2 in total

1.  First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).

Authors:  Gaku Yamamoto; Hajime Asahina; Osamu Honjo; Toshiyuki Sumi; Atsushi Nakamura; Kenichiro Ito; Hajime Kikuchi; Fumihiro Hommura; Ryoichi Honda; Keiki Yokoo; Yuka Fujita; Satoshi Oizumi; Ryo Morita; Yasuyuki Ikezawa; Hisashi Tanaka; Nozomu Kimura; Takaaki Sasaki; Noriaki Sukoh; Taichi Takashina; Toshiyuki Harada; Hirotoshi Dosaka-Akita; Hiroshi Isobe
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

2.  Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival.

Authors:  Takashi Higuchi; Norihiko Sugisawa; Jun Ho Park; Yu Sun; Guangwei Zhu; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Kentaro Igarashi; Michael Bouvet; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Transl Oncol       Date:  2020-07-10       Impact factor: 4.243
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.